11/20
08:23 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $60.00 price target on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $60.00 price target on the stock.
11/18
05:41 pm
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.
11/15
09:09 am
swtx
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report [Yahoo! Finance]
Low
Report
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report [Yahoo! Finance]
11/13
12:21 pm
swtx
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark [Yahoo! Finance]
Low
Report
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark [Yahoo! Finance]
11/13
02:26 am
swtx
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/12
11:33 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target lowered by analysts at HC Wainwright from $76.00 to $74.00. They now have a "buy" rating on the stock.
Low
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target lowered by analysts at HC Wainwright from $76.00 to $74.00. They now have a "buy" rating on the stock.
11/12
09:25 am
swtx
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
High
Report
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
11/12
06:30 am
swtx
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Low
Report
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/11
07:23 am
swtx
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q3 2024 Result [Yahoo! Finance]
Low
Report
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q3 2024 Result [Yahoo! Finance]
11/11
07:00 am
swtx
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
Low
Report
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
11/11
06:30 am
swtx
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
Low
Report
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
11/7
06:30 am
swtx
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
High
Report
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
11/5
07:00 am
swtx
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Low
Report
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
11/4
07:31 am
swtx
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
10/28
08:30 am
swtx
Process over Projects: Rethinking GxP System Validation in an Age of Rapid Change, Upcoming Webinar Hosted by Xtalks
Medium
Report
Process over Projects: Rethinking GxP System Validation in an Age of Rapid Change, Upcoming Webinar Hosted by Xtalks
10/22
07:00 am
swtx
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Low
Report
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
9/6
01:08 pm
swtx
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report? [Yahoo! Finance]
9/4
06:15 pm
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at JPMorgan Chase & Co. from $64.00 to $68.00. They now have an "overweight" rating on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at JPMorgan Chase & Co. from $64.00 to $68.00. They now have an "overweight" rating on the stock.
8/28
05:51 pm
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $77.00 price target on the stock, up previously from $75.00.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $77.00 price target on the stock, up previously from $75.00.
8/28
10:19 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $76.00 price target on the stock.
Low
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $76.00 price target on the stock.
8/28
06:30 am
swtx
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
Medium
Report
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
8/23
01:03 pm
swtx
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now [Yahoo! Finance]
Low
Report
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now [Yahoo! Finance]